uniQure Q1 net loss narrows to $65.6M; cash $555.7M; advancing AMT-130 regulatory path

uniQure N.V.

2024-Q1 EPS reported -$1.36 revenue$8,485,000

Net loss $65.6M ($1.36/sh) vs $77.2M ($1.63) in Q1 2023; revenue $8.5M vs $5.3M.
Cash $555.7M (down from $617.9M Dec 2023); expects to fund operations into Q2 2027.
On track for FDA interaction for AMT-130 in Q2 2024; clinical update mid-2024 with up to 3-year data on 29 patients.
New Phase I/II trials: Fabry disease (AMT-191) enrollment begins Q2 2024; SOD1-ALS and MTLE expected Q3 2024.
Comprehensive operational review to reduce expenses underway, completion expected mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

uniQure N.V. reported the quarter ended March 31, 2024 results: revenue $8.5 million.

Period: the quarter ended March 31, 2024
Revenue: $8.5 million
Result: reported results

Exact text from the filing

Revenue for the three months ended March 31, 2024 was $8.5 million, compared to $5.3 million in the same period in 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

uniQure N.V. filing history →

Source: SEC EDGAR

accession 0001558370-24-006916

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.